Literature DB >> 393288

Treatment of severe hypertension by repeated bolus injections of labetalol.

A M Cumming, J J Brown, A F Lever, A Mackay, J I Robertson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 393288      PMCID： PMC1429741     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  9 in total

1.  The electrocardiogram in population studies. A classification system.

Authors:  H BLACKBURN; A KEYS; E SIMONSON; P RAUTAHARJU; S PUNSAR
Journal:  Circulation       Date:  1960-06       Impact factor: 29.690

Review 2.  Labetalol: a review of its pharmacology and therapeutic use in hypertension.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

3.  Estimation of angiotensin II concentration in human plasma by radioimmunoassay. Some applications to physiological and clinical states.

Authors:  G Düsterdieck; G McElwee
Journal:  Eur J Clin Invest       Date:  1971-11       Impact factor: 4.686

4.  Labetalol in hypertension.

Authors: 
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

5.  Effect of blood pressure angiotensin II and aldosterone concentrations during treatment of severe hypertension with intravenous labetalol: comparison with propranolol.

Authors:  P M Trust; E A Rosei; J J Brown; R Fraser; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Autoregulation of brain circulation in severe arterial hypertension.

Authors:  S Strandgaard; J Olesen; E Skinhoj; N A Lassen
Journal:  Br Med J       Date:  1973-03-03

7.  Management of complicated hypertension including hypertensive emergencies.

Authors:  D W Richardson; A J Raper
Journal:  Cardiovasc Clin       Date:  1978

8.  Metabolism of labetalol by animals and man.

Authors:  L E Martin; R Hopkins; R Bland
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Ischaemic heart disease in young women.

Authors:  M F Oliver
Journal:  Br Med J       Date:  1974-11-02
  9 in total
  9 in total

Review 1.  Comparison of labetalol with other anti-hypertensive drugs.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

2.  Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium.

Authors:  B N Prichard; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

Review 3.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

Review 4.  Hypertension in pregnancy. Pathophysiology and management.

Authors:  W F Lubbe
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

5.  Intravenous labetalol in severe hypertension.

Authors:  C Dal Palu; A C Pessina; A Semplicini; M Hlede; F Morandin; P Palatini; G Sperti; G P Rossi
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 6.  Combined alpha- and beta-receptor inhibition in the treatment of hypertension.

Authors:  B N Prichard
Journal:  Drugs       Date:  1984       Impact factor: 9.546

Review 7.  Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.

Authors:  P Lund-Johansen
Journal:  Drugs       Date:  1984       Impact factor: 9.546

8.  [Effectiveness and hemodynamic mechanism of action of blood pressure lowering by intravenous labetalol in patients with a critical increase in blood pressure].

Authors:  H P Schuster; B Ehlers; K F Bodmann; F Köhler
Journal:  Klin Wochenschr       Date:  1989-07-17

9.  Diazoxide and labetalol in acute hypertension during haemodialysis.

Authors:  G Keusch; H Schiffl; U Binswanger
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.